ArticleCancer medicine2026
Clinical Outcomes of the Alternative GAMMA Regimen in Relapsed Germ Cell Tumours.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollowing promising results in a phase II trial evaluating GAMMA as salvage therapy for relapsed germ cell tumours (GCT) who had progressed on cisplatin-based chemotherapy, the GAMMA regimen was adopted into clinical practice at St Bartholomew's Hospital. This study provides the largest real-world evaluation of the GAMMA regimen to date, assessing its long-term effectiveness in an unselected patient population. METHODOLOGY: This was a single-centre retrospective study of patients who progressed following cisplatin-based chemotherapy and were treated with GAMMA regimen between November 2012 and September 2023. Data collected included clinico-pathological features, treatment details and prognostic risk scores which are International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification and International Prognostic Factor Study Group (IPFSG) score. Progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) were assessed. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test.
resultsA total of 69 patients were included with a median age of 39 years. Most were male (94%) and had an ECOG performance status of 0-1 (76%). Non-seminomatous histology was observed in 80% and 74% had a gonadal primary tumour. BEP was the most common first-line treatment (89%). Poor-risk disease per IGCCCG criteria was seen in 41% while 39% were intermediate-risk by IPFSG. 64% completed all planned chemotherapy cycles; 10% discontinued due to toxicity. Stem cell mobilisation was successful in 91%. The most frequent treatment response was partial response marker negative (PRm-) (38%). The 2-year PFS and OS rates were 31% and 49%, respectively. By IPFSG risk group, 2-year PFS and OS ranged from 20%-50% and 20%-75%. Among patients with LDH ≥ 2.5xULN, 2-year PFS was 38% and OS was 47%.
conclusionsGAMMA demonstrates acceptable tolerability and maintains meaningful survival outcomes, supporting its use as a dose-intensified salvage treatment option for patients with relapsed GCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.